Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has named David Hastings as Chief Financial Officer, effective January 6, 2026.

“I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi,” said Jennifer Good, President and CEO of Trevi Therapeutics. “His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough.”

Experience

Hastings brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies to Trevi. His accomplishments span capital raising, commercialization, business development, and investor relations management. Throughout his career, Hastings has raised over $2B in equity and debt financing.

Most recently, Hastings was Chief Financial Officer (CFO) at Arbutus from June 2018 until March 2025. Previously, he was Senior Vice President and CFO of Unilife from 2015 until 2017. Prior to that, he spent the majority of his career as CFO and Executive Vice President at Incyte, a role he held from 2003 to 2014. Hastings also previously served as Vice President, CFO and Treasurer at ArQule Inc. Currently, he is a Board member and Chair of the Audit Committee of Scynexis, Inc.

“I am happy to join Trevi as they continue to pioneer a potential treatment option for patients with chronic cough,” said Hastings. “Trevi is at an exciting stage of development with statistically significant data across target indications, limited competition, and a strong cash position. I look forward to leveraging my experience to accelerate its path to long-term value for both patients and shareholders.”